Q1 2022 Vascular Biogenics Ltd Earnings Call Transcript
Greetings, and welcome to the VBL Therapeutics' first-quarter 2022 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn this conference over to your host, Mr. Dan Ferry of LifeSci Advisors. Please go ahead, Dan.
/
Thank you, operator. Good morning, everyone, and thank you for joining the VBL Therapeutics' first-quarter 2022 financial results and corporate update call. Joining me on the call is Professor Dror Harats, Chief Executive Officer; and Sam Backenroth, Chief Financial Officer. A press release with the company's financial results was issued earlier this morning and is available on the Investor Relations page of the VBL's website at vblrx.com.
Before turning the call over to Dror and Sam, I would like to remind everyone that during this conference call, forward-looking statements made by management are intended to fall within the Safe Harbor Provisions of the Private Securities Litigation Reform
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |